17. RNAi in Respiratory Diseases

  1. Kun Cheng3 and
  2. Ram I. Mahato4
  1. Ciara Kelly1,
  2. Awadh B. Yadav1,
  3. Paul J. McKiernan2,
  4. Catherine M. Greene2 and
  5. Sally-Ann Cryan1

Published Online: 26 APR 2013

DOI: 10.1002/9781118610749.ch17

Advanced Delivery and Therapeutic Applications of RNAi

Advanced Delivery and Therapeutic Applications of RNAi

How to Cite

Kelly, C., Yadav, A. B., McKiernan, P. J., Greene, C. M. and Cryan, S.-A. (2013) RNAi in Respiratory Diseases, in Advanced Delivery and Therapeutic Applications of RNAi (eds K. Cheng and R. I. Mahato), John Wiley and Sons, Ltd, Chichester, UK. doi: 10.1002/9781118610749.ch17

Editor Information

  1. 3

    School of Pharmacy, University of Missouri-Kansas City, USA

  2. 4

    Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, USA

Author Information

  1. 1

    School of Pharmacy Royal College of Surgeons in Ireland, Ireland

  2. 2

    Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Ireland

Publication History

  1. Published Online: 26 APR 2013
  2. Published Print: 10 JUN 2013

ISBN Information

Print ISBN: 9781119976868

Online ISBN: 9781118610749

SEARCH

Keywords:

  • lung cancer;
  • cystic fibrosis;
  • chronic obstructive pulmonary disease;
  • idiopathic pulmonary fibrosis;
  • inhalation;
  • viral RNA vector;
  • nonviral RNA vector

Summary

The emergence of RNA interference (RNAi) technology, including siRNA, shRNA and miRNA modulators, offers a potentially exciting new therapeutic paradigm for a range of respiratory diseases. To deliver RNAi therapies directly to the respiratory tract via inhalation, carriers are required to protect the RNA during delivery/aerosolization and enhance cell-specific uptake to target cells. In this chapter, RNAi treatments being developed for a range of respiratory conditions are explored along with the key delivery and development issues for translating these therapies into clinical and commercial products.